Pharmaceutical combinations for the treatment of stroke and traumatic brain injury
CA 2356545 A1 · Owner: Chenard, Bertrand Leo · Inventors: Saltarelli, Mario David; Menniti, Frank Samuel; Chenard, Bertrand Leo
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
This invention relates to methods of treating traumatic brain injury (TBI) or hypoxic or, ischemic stroke, comprising administering to a patient in need of such treatment an NR2B, subtype selective N-methyl-D-aspartate (NMDA) receptor antagonist in combination with, either: (a) a sodium channel antagonist; (b) a nitric oxide synthase (NOS) inhibitor; (c) a, glycine site antagonist; (d) a potassium channel opener; (e) an AMPA/ kainate receptor, antagonist; (f) a calcium channel antagonist; (g) a GABA-A receptor modulator (e.g. a GABA-, A receptor agonist); or (h) an antiinflammatory agent. This invention also relates to methods, of treating hypoxic or ischemic stroke comprising …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 4, 2001. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended September 4, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 4, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.